Clinic Roundup

• Medivir AB, of Stockholm, Sweden, said a Phase I trial has been initiated for MIV-711, a cathepsin K inhibitor to treat bone disorders such as osteoporosis, osteoarthritis and bone metastases. MIV-711 will be administered as single-ascending oral doses to healthy volunteers, followed by daily doses for seven days.